Skip to content
PUBLISHED: | UPDATED:

Clovis Oncology (NYSE: CLVS) is increasing the number of directors on its board from 10 to 11 and filling that vacancy with Dr. Ronit Simantov, the company announced Monday in a news release.

Simantov is the chief medical officer at the cell-therapy company Gamida Cell Ltd. She had previously served as vice president for oncology global medical affairs at Pfizer Inc, with other experience at OSI Pharmaceuticals, CuraGen Corporation and Bayer HealthCare Pharmaceuticals.

Simantov will receive $55,000 in annual cash retainers for her role on the board. She will also receive a one-time option to purchase 83,212 shares of Clovis Oncology stock.

© 2021 BizWest Media LLC

Join the Conversation

We invite you to use our commenting platform to engage in insightful conversations about issues in our community. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.